Document:

Asset Purchase Agreement dated April 18, 2006

 Exhibit 10.16 
 ASSET PURCHASE AND SALE AGREEMENT 
 THIS ASSET PURCHASE AND SALE AGREEMENT (this “Agreement”) is made as of
April 18, 2006 (the “Effective Date”) by and between Biovest International, Inc., a Delaware (USA) corporation, with its offices located at 324 S. Hyde Park Avenue Suite 350, Tampa FL 33606 (“Biovest”), and Biovax, Inc., a
Florida corporation with offices located at 377 Plantation St. Worcester, Massachusetts 01605 (“Biovax.” and together with Biovest, collectively, the “Parties,” and, individually, a “Party.”), 

			
	  
	 	.

 Background 
 WHEREAS, Biovest owns certain assets attached as Exhibit A hereto constituting all or substantially all of the assets of Biovest’s vaccine manufacturing business situated at 377 Plantation Street, Worcester, MA
(the “Equipment”); and 
 WHEREAS, Biovax has expressed interest in purchasing the Equipment subject to the liabilities described
in Exhibit B (the “Assumed Liabilities”); and 
 WHEREAS, Biovest is the tenant under that certain Lease Agreement
(“Lease”) as amended attached as Exhibit C-2 with respect to portions of premises located at 377 Plantation Street, Worcester MA (the “Leasehold”) and the letter of Intent attached as Exhibit D with the landlord of the Leased
Premises to potentially lease additional space adjacent to the leased premises attached (the “Letter of Intent for Expanded Lease Premises”); and 
 WHEREAS, Biovax has expressed interest in subleasing from Biovest all rights and assuming all obligations pursuant to the Lease Premises and assuming all rights under the Letter of Intent for Expanded lease Premises
and in making a deposit in the amount of $4,500,000 as an advance payment of rent ; and 
 WHEREAS, the parties wish to set forth the terms
and conditions pursuant to which Biovax will serve as a contract manufacturer for Biovest for anti-cancer vaccine, including anti-cancer vaccine used by Biovest in its clinical trial. 
 WHEREFORE, in consideration of the foregoing and the mutual covenants contained herein and other consideration, the receipt and sufficiency of which are
hereby acknowledged, and intending to be legally bound, Biovax and Biovest hereby agree as follows: 
 1. Definitions 
 (a) “Equipment” means all of the assets of Biovest’s manufacturing business situated at 377 Plantation Street, Worcester, MA as listed in Exhibit A.

 (b) “Leasehold” means Biovest’s Lease for portions of the facility located at 377 Plantation Street, Worcester MA as described in
Exhibit C-2. 
 (c) “As is/Where is” means that the Equipment is being offered for sale at a price discounted from its cost basis in its
current condition at its current location. 
 (d) “Business Description” means the description of the business of manufacturing vaccines as more
fully described in Exhibit H hereto. 
 2. Purchase and Sale of Equipment. 
 At Closing, Biovax will purchase and Biovest will sell the Equipment As is/Where is subject to no debts liens or liabilities except those described on Exhibit B. 
 3. Sublease. 
 At Closing, Biovax will sublease the Leasehold
subject to all obligations under the Lease attached as Exhibit C-2. and Biovest will sublease the Leasehold to Biovax. 

 At Closing, Biovax will assume all rights subject to all obligations to Letter of Intent for Expanded Leased Premises
from Biovest and Biovest agrees to assign to Biovax all rights subject to all obligations to Letter of Intent for Expanded Leased Premises. 
 4.
Pricing and Payment Terms. 
 As the full purchase price for the Equipment, Biovax shall pay to Biovest $1,500,000.00 (the “Equipment Purchase
Price”). The Equipment Purchase Price shall be paid within ten days following Closing 
 As consideration for the sublease of the Premises and the
assignment of the Letter of Intent for the Expanded Leased Premises, Biovax shall within ten days following Closing deposit, with Biovest advance rental payments for the Leasehold in the amount of $4,500,000 (“Rent Payment”). Biovest will
treat the Rent Payment as unrestricted and nonsegregated funds provided that Biovest shall use the Rent Payment to make all required lease payments on the Lease Premises and Expanded Lease Premises if any until the Rent Payment is consumed.

 As consideration for the consent to hiring of the Worcester Employees identified on Exhibit E, Biovax shall agree to hire those employees at their current
salary levels and to assume responsibility for all accrued vacation time and maintenance of existing health and other insurance benefits. 
 5.
Closing. 
 The closing shall take place at 377 Plantation Street, Worcester MA on Thursday April 20, 2006 at 10 am (the “Closing”). At
the Closing, the parties shall deliver the following: 
 Biovax shall deliver to Biovest: 
  

	 	1.	Payment of Purchase Price and Rent Payment. 

  

	 	2.	Executed Sublease. 

  

	 	3.	Assumption of Liabilities listed in Exhibit B. 

  

	 	4.	Form of Notice to Employees regarding hiring by Biovax substantially in the form of Exhibit F. 

 Biovest shall deliver to Biovax: 
  

	 	1.	Executed Bill of Sale for the Equipment substantially in the form of Exhibit G. 

  

	 	2.	Executed Assignment of Lease and Letter of Intent for Expansion Lease Premises substantially in the form of Exhibit C-1 and D. 

  

	 	3.	Consent to Hiring of Worcester Employees listed on Exhibit E. 

 6.
Contract Manufacturer. 
 As more fully described in the Business Description, Biovax shall serve as a non-exclusive contract manufacturer to
manufacture anti-cancer vaccines for Biovest as and when ordered and pursuant to required specifications submitted in writing by Biovest and accepted by Biovax. All vaccines manufactured by Biovax for Biovest shall be paid for at a manufactured cost
equal to the fully burdened manufactured cost plus 20%. Biovax’s fully burdened cost includes all third party and overhead expenses, such as wages and salaries, lease payments, utilities, purchases of manufacturing materials, maintenance and
repairs to equipment and leasehold, amortization, and other expenditures 

  

 - 2 - 

 
necessary or appropriate to operate the Lease Premises currently accrued, using the same methodology as currently used in Biovest financial accounting. Fully
burdened costs do not include capital expenditures such as purchases of equipment and partially completed vaccines, expansion of facilities, leasehold improvements, and employee training. Biovest shall have the right to inspect and audit the
calculation of full burdened manufactured cost upon reasonable notice to Biovax. Invoices shall be paid within 30 days after invoice. In addition to the foregoing amounts, for so long as Biovest requires vaccines to be manufactured by Biovax for the
Biovest clinical trial, Biovest shall pay to Biovax an amount equal to $250,000 per annum. Nothing herein shall prohibit Biovax from engaging in other manufacturing activities utilizing the Equipment, Leasehold and Worcester employees; provided,
that in the event of any such other activities, expenses shall be appropriately apportioned to determine the fully burdened costs of the vaccines manufactured for Biovest. 
 7. Shared Support Services. Biovax shall be entitled to, but shall not be obligated to, purchase support services such as HR support, IT support, accounting support and legal support ,from
Biovest. The purchase price shall be an amount equal to the allocated cost to Biovest for providing such services purchased by Biovax in its discretion. 
 8. No Interest in Vaccine or Intellectual Property of Biovest. 
 Biovax will not acquire, by virtue hereof, any interest in any
property of Biovest not expressly transferred hereunder. In expansion of, and not in limitation of, the forgoing, it is expressly agreed and acknowledged that Biovax shall have no interest in, right to use or ownership of Biovest’s anti-cancer
vaccine, any patent or proprietary property of Biovest, the Investigational New Drug Applications owned by Biovest, the clinical trials being conducted by Biovest, and that certain Cooperative Research and Development Agreement between The National
Cancer Institute and Biovest. 
 9 Exclusion of Warranty. 
 BIOVEST MAKES NO WARRANTIES, EXPRESS OR IMPLIED, WITH RESPECT TO THE EQUIPMENT, AND HEREBY SPECIFICALLY DISCLAIMS ALL IMPLIED AND STATUTORY WARRANTIES, BY OPERATION OF LAW OR OTHERWISE, INCLUDING WITHOUT LIMITATION WARRANTIES OF
MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, AND NON-INFRINGEMENT OF A PATENT, TRADEMARK, OR OTHER INTELLECTUAL PROPERTY RIGHT. NO REPRESENTATION OR OTHER AFFIRMATION OF FACT, INCLUDING BUT NOT LIMITED TO STATEMENTS REGARDING CAPACITY,
SUITABILITY FOR USE OR PERFORMANCE OF THE CUSTOMIZED SYSTEM, WHETHER MADE BY BIOVEST EMPLOYEES OR OTHERWISE, WHICH IS NOT CONTAINED IN THIS AGREEMENT, SHALL BE DEEMED TO BE A WARRANTY BY BIOVEST FOR ANY PURPOSE OR GIVE RISE TO ANY LIABILITY OF
BIOVEST WHATSOEVER. 
 10. Limitation of Liability. 
 Biovax acknowledges that the Equipment is sold “As is/Where is” and that in no event will Biovest retain any liability for the Equipment sold under the terms of this agreement. 
 At and after the date of assignment of the Leasehold, Biovax hereby agrees to make all payments of rent and additional rent called for in the Leasehold documents and to
otherwise comply with all covenants and obligations of Biovest with respect to the Leasehold. 
 11. Governing Law. 
 This Agreement shall be construed and enforced in accordance with the laws of the State of Delaware without regard for its provisions with respect to conflict of laws.

  

 - 3 - 

 12. Jurisdiction 
 Any
claim, suit, action or proceeding initiated by any Party (whether in contract, tort or otherwise) arising out of this Agreement or the relationship of the parties hereunder, shall be filed and prosecuted only in the state or federal courts in the
State of Massachusetts, which the Parties agree shall have exclusive jurisdiction over such matters and the Parties agree to submit to the jurisdiction of such courts. Each of the Parties, to the extent permitted by applicable law, hereby waives and
agrees not to assert, by way of motion, as a defense or otherwise, in any such suit, action or proceeding, any claim that it is not subject personally to the jurisdiction of the above-referenced courts, that its property is exempt or immune from
attachment or execution, that the suit, action or proceeding is brought in an inconvenient forum, that the venue of the suit, action or proceeding is improper or that this Agreement or the subject matter hereof may not be enforced in or by such
court. Each of the Parties hereby agrees that its submission to jurisdiction is made for the express benefit of the other Party hereto. 
 13. Termination

 This Agreement may, by notice given prior to its performance, be terminated 
 a. by mutual consent of the Parties; or 
 b. by either Party, if the Closing has not occurred (other than through the
failure of such Party to comply with its obligations under this Agreement) by the close of business on April 21, 2006 (the “Drop Dead Date”). 
 In the event of termination of this Agreement pursuant to this Section 12, this Agreement shall forthwith become void and of no further force and effect and the parties hereto shall be released from any and all obligations hereunder.

 14. Binding Effect. 
 This Agreement shall be binding
upon the Parties hereto and their respective successors and assigns; provided, however, that neither this Agreement nor any Party’s rights or obligations hereunder may be assigned, or held in trust for a third-party, by any Party hereto without
the prior written consent of the other Party, except that Biovest may assign or transfer this Agreement to any affiliate or subsidiary of Biovest. 
 15.
Waiver of Conditions. Exhibits. 
 Any Party hereto may waive any condition provided in this Agreement for its benefit. All of the Exhibits attached to
this Agreement are hereby incorporated herein and made a part hereof. 
 16. Notices. 
 Any notice, authorization, request or demand required or permitted to be given hereunder shall be in writing and shall be deemed to have been duly given on the earlier of (i) the date when received by the
addressee, if sent by overnight courier or delivered personally, (ii) when confirmation is confirmed by the sender’s fax machine, if sent by facsimile, provided that a copy thereof is also contemporaneously sent to the addressee by a
method described in clauses (i) or (iii) of this Section 15, or (iii) the fifth business day after the date when posted, if sent by registered or certified mail, in any such case to the respective addresses specified in the
introductory paragraph of this Agreement. 
 Any Party may, by written notice delivered in accordance with this Section 15, change the address to which
any notices, authorizations, requests or demands are to be delivered hereunder. 
  

 - 4 - 

 17. Counterparts. 
 This Agreement may be executed in two or more counterparts, each of which shall be binding as of the date first written above. Each such copy shall be deemed an original, and it shall not be necessary in making proof of this Agreement
to produce or account for more than one such counterpart. 
 18. Amendment. 
 This Agreement may be amended at any time pursuant to a written instrument signed by the Parties. 
 19. Interpretation. 
 Unless the context of this Agreement clearly
requires otherwise, (a) references to the plural include the singular, the singular the plural, the part the whole, (b) references to any gender include all genders, (c) “including” has the inclusive meaning frequently
identified with the phrase “but not limited to,” (d) the word “or” shall be deemed to be inclusive, and (e) references to “hereunder” or “herein” relate to this Agreement. The section and other
headings contained in this Agreement are for reference purposes only and shall not control or affect the construction of this Agreement or the interpretation thereof in any respect. Section, subsection, and Exhibit references are to this Agreement
unless otherwise specified. Capitalized terms set forth in the Exhibits attached hereto shall have the same meanings as set forth in this Agreement, unless defined otherwise in such Exhibit. 
 20. Construction. 
 The Parties agree and acknowledge that they have
jointly participated in the negotiation and drafting of this Agreement. In the event of an ambiguity or question of intent or interpretation arises, this Agreement shall be construed as if drafted jointly by the Parties and no presumptions or
burdens of proof shall arise favoring any Party by virtue of the authorship of any of the provisions of this Agreement. 
 21. No Third Party Rights.

 Nothing in this Agreement shall be deemed to create any right on the part of any person or entity not a party to this Agreement. 
 22. Waiver of Jury Trial. 
 The Parties specifically waive any right
to trial by jury in any court with respect to any contractual, tortious or statutory claim, counterclaim or cross-claim against the other arising out of or connected in any way to this Agreement because the parties hereto, both of whom are
represented by counsel, believe that the complete commercial aspect of their dealing with one another make a jury determination neither desirable nor appropriate. 
 [THIS SPACE INTENTIONALLY LEFT BLANK] 
  

 - 5 - 

 IN WITNESS WHEREOF, the parties hereto have duly executed this Agreement as of the date first above
written.
  

			
		 	Biovax, Inc.
	
	 /s/ James A. McNulty

	Signature
	
	  

	Date	 	
		
	By:	 	James A. McNulty
	Name:	 	
	Its:	 	CFO and Secretary
	Hereunto duly authorized

  
  

			
		 	Biovest International, Inc.
	
	  
 /s/ Steve Arikian

	Signature
	
	  

	Date	 	
		
	By:	 	Steve Arikian
	Name:	 	
	Its:	 	CEO/Chairman
	Hereunto duly authorized

  

 - 6 -Vaccine Purchase and Sale Agreement

 Exhibit 10.17 
 VACCINE PURCHASE AND SALE AGREEMENT 
 THIS VACCINE PURCHASE AND SALE AGREEMENT (this “Agreement”) is made as of
April 28, 2006 (the “Effective Date”) by and between Biovax, Inc., a Florida corporation with offices located at 377 Plantation St., Worcester, Massachusetts 01605 (“Biovax”) and Biovest International, Inc., a Delaware
corporation, with its offices located at 324 S. Hyde Park Avenue Suite 350, Tampa, Florida 33606 (“Biovest” and with Biovax, the “Parties” or singularly a “Party”). 
 Background 
 WHEREAS, Biovest is in various
stages of manufacturing certain Vaccines; 
 WHEREAS, Biovax desires to purchase the Vaccines; and 
 WHEREAS, the Parties wish to set forth the terms and conditions pursuant to which Biovax will purchase these Vaccines from Biovest. 
 WHEREFORE, in consideration of the foregoing and the mutual covenants contained herein and other good and valuable consideration, the receipt and
sufficiency of which are hereby acknowledged, and intending to be legally bound, Biovax and Biovest hereby agree as follows: 
 1. Definitions

 (a) “Vaccines” means twenty-five (25) vaccines in various stages of being manufactured for use in Biovest’s ongoing clinical
trial for treatment of Follicular Non-Hodgkins lymphoma. 
 (b) “Payables” means Biovest’s outstanding Accounts Payable incurred in
connection with the manufacture of the Vaccines prior to the sale of all or substantially all of its assets specifically related to its vaccine manufacturing business to Biovax, as listed in Exhibit A. 
 (c) “Closing” means a date and time as mutually agreed to by the Parties upon which all transactions contemplated herein will take place simultaneously,
and where the Parties shall deliver an executed Bill of Sale substantially in the form of Exhibit B attached hereto and all other documents deemed necessary and reasonable to consummate the transactions set forth in this Agreement, and no
transaction shall be deemed to have been completed and no documents or certificates shall be deemed delivered until all other transactions are completed and all other documents and certificates are delivered. 
 2. Purchase and Sale of Vaccines. 
 Upon and subject to the terms and
conditions of this Agreement, Biovax shall purchase from Biovest and Biovest shall sell, transfer, convey, assign and deliver to Biovax, at the Closing, for the consideration set forth in Section 3 below, all right, title and interest in, to
and under the Vaccines subject to no debts, liens or liabilities, except those specifically being assumed by Biovax and set forth on Exhibit A. 

 3. Pricing and Payment Terms; Further Assurances. 
 As the full purchase price and consideration for the Vaccines, Biovax shall assume the liabilities set forth on Exhibit A in a maximum amount of $1,325,000 (the “Assumed Liabilities”). At any time and from
time to time after the Closing, at the request of Biovax and without further consideration, Biovest shall execute and deliver such other instruments of sale, transfer, conveyance and assignment and take such actions as Biovax may reasonably request
to more effectively transfer, convey and assign to Biovax, and to confirm Biovax’s rights to, title in and ownership of, the Vaccines. 
 4.
Representations and Warranties. 
 Each of the Parties (i) is an entity in good standing in their respective states of incorporation and is
qualified to do business in all necessary foreign jurisdictions as so legally required, and (ii) has all the requisite power and authority to execute and deliver this Agreement to which it is a party and to perform its obligations hereunder.

 5. No Interest in Intellectual Property of Biovest. 
 Biovax will acquire no interest in any property of Biovest not expressly sold, transferred, conveyed, assigned and delivered hereunder. In expansion of, and not in limitation of, the forgoing, it is expressly agreed and acknowledged that
Biovax shall have no interest in, right to use or ownership of Biovest’s anti-cancer vaccine, with the exception of the Vaccines expressly sold, transferred, conveyed, assigned and delivered hereunder, any patent or proprietary property of
Biovest, the IND owned by Biovest, the clinical trials being conducted by Biovest, or the CRADA between Biovest and the NCI. 
 6. Exclusion of
Warranty. 
 BIOVEST MAKES NO WARRANTIES, EXPRESS OR IMPLIED, WITH RESPECT TO THE VACCINES, AND HEREBY SPECIFICALLY DISCLAIMS ALL IMPLIED AND STATUTORY
WARRANTIES, BY OPERATION OF LAW OR OTHERWISE, INCLUDING WITHOUT LIMITATION WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, AND NON-INFRINGEMENT OF A PATENT, TRADEMARK, OR OTHER INTELLECTUAL PROPERTY RIGHT. NO REPRESENTATION OR OTHER
AFFIRMATION OF FACT, INCLUDING BUT NOT LIMITED TO STATEMENTS REGARDING CAPACITY, SUITABILITY FOR USE OR PERFORMANCE, WHETHER MADE BY BIOVEST EMPLOYEES OR OTHERWISE, WHICH IS NOT CONTAINED IN THIS AGREEMENT, SHALL BE DEEMED TO BE A WARRANTY BY
BIOVEST FOR ANY PURPOSE OR GIVE RISE TO ANY LIABILITY OF BIOVEST WHATSOEVER. 
  

 - 2 - 

 7. Limitation of Liability. 
 Biovax acknowledges that the Vaccines are sold “As is” and that in no event will Biovest retain any liability whatsoever for the Vaccines sold under the terms of this Agreement. 
 8. Governing Law. 
 This Agreement shall be construed and enforced in
accordance with the laws of the State of Delaware, without regard for its provisions with respect to conflict of laws. 
 9. Jurisdiction. 

Any claim, suit, action or proceeding initiated by any of the Parties (whether in contract, tort or otherwise) arising out of this Agreement or the relationship of the
Parties hereunder, shall be filed and prosecuted only in the state or federal courts in the State of Massachusetts, which the Parties agree shall have exclusive jurisdiction over such matters and the Parties agree to submit to the jurisdiction of
such courts. Each of the Parties, to the extent permitted by applicable law, hereby waives and agrees not to assert, by way of motion, as a defense or otherwise, in any such suit, action or proceeding, any claim that it is not subject personally to
the jurisdiction of the above-referenced courts, that its property is exempt or immune from attachment or execution, that the suit, action or proceeding is brought in an inconvenient forum, that the venue of the suit, action or proceeding is
improper or that this Agreement or the subject matter hereof may not be enforced in or by such court. Each of the Parties hereby agrees that its submission to jurisdiction is made for the express benefit of the other Party hereto. 
 10. Termination. 
 This Agreement
may, by notice given prior to its performance, be terminated as follow: 
 a. by mutual consent of the Parties; or 
 b. by either Party, if the Closing has not occurred (other than through the failure of such Party to comply with its obligations under this Agreement) by the close of
business on May 31, 2006 (the “Drop Dead Date”). 
 In the event of termination of this Agreement pursuant to this Section, this Agreement
shall forthwith become void and of no further force and effect and the Parties hereto shall be released from any and all obligations hereunder. 
 11.
Binding Effect. 
 This Agreement shall be binding upon the Parties hereto and their respective successors and assigns; provided, however, that neither
this Agreement nor any Party’s rights or 
  

 - 3 - 

 obligations hereunder may be assigned, or held in trust for a third-party, by any Party hereto without the prior written
consent of the other Party, except that Biovest may assign or transfer this Agreement to any affiliate or subsidiary of Biovest. 
 12. Waiver of
Conditions; Exhibits. 
 Any Party hereto may waive any condition provided in this Agreement for its benefit. All of the Exhibits attached to this
Agreement are hereby incorporated herein and made a part hereof. 
 13. Notices. 
 Any notice, authorization, request or demand required or permitted to be given hereunder shall be in writing at the address reflected in Biovest’s books and records and shall be deemed to have been duly given on
the earlier of (i) the date when received by the addressee, if sent by overnight courier or delivered personally, (ii) when confirmation is confirmed by the sender’s fax machine, if sent by facsimile, provided that a copy thereof is
also contemporaneously sent to the addressee by a method described in clauses (i) or (iii) of this Section, or (iii) the fifth business day after the date when posted, if sent by registered or certified mail, in any such case to the
respective addresses specified in the introductory paragraph of this Agreement. 
 Any Party may, by written notice delivered in accordance with this
Section, change the address to which any notices, authorizations, requests or demands are to be delivered hereunder. 
 14. Counterparts. 

This Agreement may be executed in two or more counterparts, each of which shall be binding as of the date first written above. Each such copy shall be deemed an
original, and it shall not be necessary in making proof of this Agreement to produce or account for more than one such counterpart. 
 15. Amendment.

 This Agreement may be amended at any time pursuant to a written instrument signed by the Parties. 
 16. Interpretation. 
 Unless the context of this Agreement clearly
requires otherwise, (a) references to the plural include the singular, the singular the plural, the part the whole, (b) references to any gender include all genders, (c) “including” has the inclusive meaning frequently

  

 - 4 - 

 identified with the phrase “but not limited to,” (d) the word “or” shall be deemed to be
inclusive, and (e) references to “hereunder” or “herein” relate to this Agreement. The section and other headings contained in this Agreement are for reference purposes only and shall not control or affect the construction
of this Agreement or the interpretation thereof in any respect. Section, subsection, and Exhibit references are to this Agreement unless otherwise specified. Capitalized terms set forth in the Exhibits attached hereto shall have the same meanings as
set forth in this Agreement, unless defined otherwise in such Exhibit. 
 17. Construction. 
 The Parties agree and acknowledge that they have jointly participated in the negotiation and drafting of this Agreement. In the event of an ambiguity or question of
intent or interpretation arises, this Agreement shall be construed as if drafted jointly by the Parties and no presumptions or burdens of proof shall arise favoring any Party by virtue of the authorship of any of the provisions of this Agreement.

 18. No Third Party Rights. 
 Nothing in this Agreement
shall be deemed to create any right on the part of any person or entity not a party to this Agreement. 
 19. Waiver of Jury Trial. 
 The Parties specifically waive any right to trial by jury in any court with respect to any contractual, tortious or statutory claim, counterclaim or cross-claim against
the other arising out of or connected in any way to this Agreement because the Parties hereto, both of whom are represented by counsel, believe that the complete commercial aspect of their dealing with one another make a jury determination neither
desirable nor appropriate. 
 [THIS SPACE INTENTIONALLY LEFT BLANK] 
  

 - 5 - 

 IN WITNESS WHEREOF, the Parties hereto have duly executed this Agreement as of the date first above written.

 

			
	Biovax, Inc.
	
	  

	Signature	 	
	
	  

	Date	 	
		
	By:	 	  

	Name:	 	
	Its:	 	
	
	Biovest International, Inc.
	
	  

	Signature	 	
	
	  

	Date	 	
		
	By:	 	  

	Name:	 	
	Its:	 	

 [SIGNATURE PAGE TO THE VACCINE ASSET PURCHASE AGREEMENT] 

 Exhibit A 

 Exhibit B 
 Bill of Sale

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00102-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00102-of-00352.parquet"}]]